Lantanon

Mianserin hydrochloride, the active ingredient in Lantanon, is a tetracyclic antidepressant presented as an oral tablet for oral administration. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood and functional capacity.

GNH USA supplies Lantanon as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide through a regulated distribution network that ensures quality and traceability. The company adheres to global standards for manufacturing and packaging, supporting reliable access to essential medicines.

Lantanon (mianserin) is used primarily within the antidepressant therapeutic class to manage depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood in adult patients. - Depressive disorder with anxiety: reduces anxiety components that accompany depressive episodes. - Insomnia associated with depression: provides sedative effects that help improve sleep quality in depressed individuals.

Mianserin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to a parched sensation. - Weight gain: increased appetite and body weight. - Constipation: difficulty passing stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Seizures: episodes of uncontrolled electrical activity in the brain. - Severe hypotension: marked drop in blood pressure causing faintness. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening. - Hepatic injury: liver dysfunction indicated by abnormal enzymes. - Suicidal thoughts: emergence or worsening of suicidal ideation.

When prescribing or dispensing Mianserin, several safety considerations are recommended.

- Monitor blood pressure: watch for orthostatic hypotension, especially at treatment initiation. - Assess suicidal risk: evaluate patients for emergent or worsening suicidal thoughts. - Avoid abrupt discontinuation: taper the dose to reduce withdrawal symptoms. - Caution in hepatic impairment: adjust dosing and monitor liver function tests. - Use cautiously in the elderly: start with low doses and monitor for sedation. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Mianserin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents: increased serotonin toxicity. - Central nervous system depressants: enhanced sedation and respiratory depression. - Alcohol: potentiates sedative effects. - Antihistamines: additive anticholinergic burden.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise mianserin plasma levels. - Antihypertensives: additive blood‑pressure lowering effect. - Anticholinergic drugs: increased risk of dry mouth and constipation. - Lithium: potential for enhanced neurotoxic effects. - Warfarin: possible alteration of INR, requiring monitoring.